Clinical Trials Logo

Clinical Trial Summary

Background and purpose: The research team developed the PelviSense, a non-invasive biofeedback device paired with wearable EMG sensors for use as a PFMT adjunct. The proposed study aims to (1) investigate the efficacy of PelviSense-assisted PFMT compared with unassisted PFMT on SUI in women, and (2) identify the mechanisms underlying the beneficial effects of PFMT for the treatment of SUI. Methods: A two-arm, parallel-group RCT will be conducted using 132 non-pregnant women with SUI, aged 18-60 years. The study participants will be randomised into two study groups: PelviSense-assisted PFMT or unassisted PFMT. Women will be supervised in the performance of PelviSense-assisted and unassisted PFMT on a 1:1 basis for 4 weeks and instructed to perform unsupervised home exercises for 24 weeks after the completion of supervised training. The primary outcome will be the severity of urine loss, as measured using the one-hour pad test. Secondary outcomes will include quality of life, SUI symptoms severity, and PFM strength, as measured using the incontinence impact questionnaire, short-form, international consultation on incontinence questionnaire, short-form, and modified Oxford scale, respectively. Mediator variables will include the following: bladder neck elevation and levator hiatus area. Outcomes and mediator variables will be assessed at baseline, 4, and 28 weeks. Statistical analysis: Treatment and mediation effects will be evaluated using analysis of covariance and the Hayes' PROCESS macro, respectively.


Clinical Trial Description

Background and purpose: Stress urinary incontinence (SUI) is a common condition among women, resulting in urine leakage during physical exertion, sneezing, or coughing. Due to the risks associated with surgical and pharmacological treatments, women with SUI often prefer conservative treatments, such as pelvic floor muscle (PFM) training (PFMT). PFMT has been shown to provide increased beneficial effects when combined with electromyography (EMG) biofeedback (referred to as conventional biofeedback [CB]) via intravaginal probe than when performed alone. However, the CB device applied in clinical practice is not preferred by women because it is invasive, and involves the insertion of a probe into the vagina, causing pain/ discomfort. Therefore, we developed the PelviSense, a non-invasive biofeedback device paired with wearable EMG sensors for use as a PFMT adjunct. The proposed study aims to (1) investigate the efficacy of PelviSense-assisted PFMT compared with unassisted PFMT on SUI in women, and (2) identify the mechanisms underlying the beneficial effects of PFMT for the treatment of SUI. Hypotheses: (1) women assigned to the PelviSense-assisted PFMT group will report a greater reduction in the severity of urine loss compared with women assigned to the unassisted PFMT group; and (2) improvements in the severity of urine loss will be mediated by increased PFM strength, causing an increase in bladder neck elevation and a reduction in levator hiatus (LH) area during the Valsalva manoeuvre. Methods: A two-arm, parallel-group RCT will be conducted using 132 non-pregnant women with SUI, aged 18-60 years. The study participants will be randomised into two study groups: PelviSense-assisted PFMT or unassisted PFMT. Women will be supervised in the performance of PelviSense-assisted and unassisted PFMT on a 1:1 basis for 4 weeks and instructed to perform unsupervised home exercises for 24 weeks after the completion of supervised training. Recruitment. Potential participants will be recruited using a non-probability convenience sampling technique through public and university campus advertising. Randomisation and blinding. An individual who will not be involved in study recruitment will randomly assign participants to one of the two study groups (PelviSense assisted PFMT or unassisted PFMT) at a 1:1 ratio. Another individual will assign treatments according to a computer-generated random schedule in permuted blocks of two within age strata. The allocation sequence will be concealed using sealed, opaque, sequentially numbered envelopes containing the group name and a personal identification number. To eliminate expectation effects and biases, a research assistant (RA) will complete the assessment of primary outcomes, and intervention training and supervision at HK PolyU will be conducted by a physiotherapy research postgraduate (RPg) student. Raw data will be double entered into a spreadsheet by a student assistant. Data analysis will be completed in a blinded manner, with code names (Groups A and B) used for each group, and group identities will only be revealed after the analysis has been completed. Procedure and baseline assessment. Potential participants will be invited to an in-person visit at HK PolyU. On the first day of contact, the participants will complete a screening questionnaire and a 1-h pad test to determine eligibility. Written informed consent and body mass index (BMI) measurements will also be obtained. The 1-h pad test, International Consultation on Incontinence Questionnaire, Short Form (ICIQ-SF), the Incontinence Impact Questionnaire, Short Form (IIQ-7), and the MOS will be used to establish baseline severity of urine loss, SUI symptoms severity, QoL, and PFM strength, respectively. Participants will undergo a transabdominal ultrasound (TAU) to measure baseline bladder neck elevation and LH area during a Valsalva manoeuvre (cough). Following baseline assessments, participants will select an envelope containing treatment allocation details. Outcome measures: The primary outcome will be the severity of urine loss, as measured using the one-hour pad test. Secondary outcomes will include quality of life, SUI symptoms severity, and PFM strength, as measured using the incontinence impact questionnaire, short-form, international consultation on incontinence questionnaire, short-form, and modified Oxford scale, respectively. Mediator variables will include the following: bladder neck elevation and levator hiatus area. Outcomes and mediator variables will be assessed at baseline, 4, and 24 weeks. Statistical analysis: Treatment and mediation effects will be evaluated using analysis of covariance and the Hayes' PROCESS macro, respectively. Statistical analysis. Hypothesis 1: Treatment effects on both primary and secondary outcomes between T1, T2, and T3 and across the intervention groups will be evaluated using analysis of covariance (ANCOVA). Hypothesis 2: Mediation analyses will be conducted using the Hayes PROCESS SPSS macro (v2.13), Model 4. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT06126757
Study type Interventional
Source The Hong Kong Polytechnic University
Contact Gladys Cheing, PhD
Phone 2766
Email gladys.cheing@polyu.edu.hk
Status Recruiting
Phase N/A
Start date November 1, 2023
Completion date December 31, 2025

See also
  Status Clinical Trial Phase
Recruiting NCT04829357 - Post Market Clinical Follow-up Study on TVT ABBREVO® Continence System
Completed NCT05493735 - Lidocaine for Pessary Check Pain Reduction Phase 3
Completed NCT04512053 - A Phase 2 Study of TAS-303 in Female Patients With Stress Urinary Incontinence Phase 2
Active, not recruiting NCT06224335 - Measurement of Intravaginal and Intra-abdominal Pressure and Pad Test During Sports Activities (SPORTVAGPRES)
Recruiting NCT05304312 - The Role of Kegel Exercises Book to Improve Treatment in Stress Urinary Incontinence Women N/A
Not yet recruiting NCT05527665 - Sexual Fonction and Discomfort in Women After Midurethral Sling Surgery, Using PPSSQ
Not yet recruiting NCT04558762 - Ten Years Follow-up After Insertion of a MUS (Mid Urethral Sling) Due to Stress Urinary Incontinence
Withdrawn NCT02524366 - A Study of Transcorporal Versus Standard Artificial Urinary Sphincter Placement N/A
Completed NCT01924728 - Efficacy of Magnetic Stimulation for Stress Urinary Incontinence N/A
Completed NCT01676662 - Solace European Confirmatory Trial N/A
Unknown status NCT01455779 - Lyrette: Renewing Continence Objective and Subjective Efficacy Study N/A
Terminated NCT01029106 - Gynecare TVT Secur for the Management of Stress Urinary Incontinence (SUI) N/A
Completed NCT01123096 - Is the Cough Stress Test Equivalent to the 24 Hour Pad Test in the Assessment of Stress Incontinence? N/A
Withdrawn NCT00573703 - Laparoscopic Burch Colposuspension Versus Transobturatory Tape for the Treatment of Female Urinary Stress Incontinence Phase 4
Completed NCT01770691 - Preliminary Performance Study of the New TIPI Device in the Prevention of Stress Urinary Incontinence N/A
Completed NCT00234754 - Trans-Obturator Tape Versus Trans-Vaginal Tape for Stress Urinary Incontinence in Women N/A
Completed NCT00441454 - Retropubic vs. Transobturator Tension-free Vaginal Tape N/A
Completed NCT03985345 - Prospective Evaluation of the Connected EMY Biofeedback Probe in the Management of Stress Urinary Incontinence. N/A
Active, not recruiting NCT03671694 - Laser Vaginal Treatment for SUI N/A
Completed NCT04097288 - Effects of Single Dose Citalopram and Reboxetine on Urethral and Anal Closure Function on Healthy Female Subjects Phase 1